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Abstract
Introduction: Recent advancements in the management of colorectal liver metastases have resulted in
an improvement in survival. Novel biomarkers such as KRAS, and their mutations potentially predict the
response of biological therapies such as cetuximab (Erbitux). This paper evaluates the use of cetuximab
in the first-line management of colorectal liver metastases.
Methods: An electronic literature search was performed of publications within the past 6 years. The
following key words, singly or in combination, were used: KRAS, cetuximab, metastatic colorectal cancer
and colorectal liver metastases. All randomized controlled trials and cohort studies were included.
Results: Fifteen prospective studies reviewed the clinical application of cetuximab. Seven studies
included sub-group analysis of KRAS mutational status, with only one study performed prospectively.
Until the MRC COIN trial, the evidence consistently demonstrated cetuximab significantly improved
progression-free survival, overall survival and surgical resection rates, especially in KRAS wild-type
tumours. However, the MRC COIN trial found cetuximab had no additional benefit when combined with
standard chemotherapy.
Conclusions: The literature does not support the routine use of cetuximab as the standard first-line
treatment of colorectal liver metastases, rather highlighting the need for the optimization of treatment on
an individual basis, especially depending on tumour KRAS status.
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Introduction
Metastatic colorectal cancer (mCRC) and its management pose a
dilemma worldwide.Around 110 new cases of colorectal cancer are
diagnosed daily, and 39 991 new cases were registered in the UK in
2008.1 In total, 30–40% of these patients will re-present with
recurrent disease, often within the first 2 years of the initial treat-
ment, with the common site for metastatic spread being the liver.2
The management of mCRC is multi-modal, and recent
advancements in oncological and surgical management, with
new-targeted therapies available, have resulted in an overall
improvement in survival in this subgroup of patients. The widely
used chemotherapy agents for the treatment of colorectal cancer
include 5-fluorouracil (5-FU) in combination with folinic acid
(FA) and oxaliplatin. In the setting of metastatic disease, 5-FU in
combination with folinic acid has been shown to prolong survival
by up to 12 months.3
In the last decade new targets have been identified for the treat-
ment of colorectal cancer and their subsequent metastases. Novel
candidate biomarkers are thought to be of both prognostic
and diagnostic value. One such biomarker, v-Ki-ras2Kirsten rat
sarcoma viral oncogene homologue (KRAS), a GTPase protein,
may prove vital in determining a patient’s response to certain
chemotherapy/biological agents in the setting of metastatic color-
ectal cancer.4 Activated KRAS mutations have a role in oncogenic
transformation during the development of colorectal cancer, and
data would suggest they have a prevalence of 30–40% in colorectal
cancer patients. The KRAS gene may be normal (wild type) or
mutated, in the mutated form unregulated proliferation and
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impaired differentiation is promoted. These mutations are
thought to potentially predict the response of biological therapies
such as cetuximab (Erbitux, Merck Serono, Geneva, Switzerland),
as those patients harbouring KRAS mutations may not benefit
from these drugs.
Cetuximab is a recombinant monoclonal antibody that blocks
the human epidermal growth factor receptor (EGFR) and there-
fore inhibits the proliferation of cells that depend on EGFR
activation for growth. The BOND trial investigated patients’
refractory to irinotecan, and found cetuximab in isolation was
associated with a response rate of 10.8% and a median survival of
6.9 months. When combined with other treatments, the response
rate improved to 22.9% and a median survival of 8.6 months.5
This resulted in the approval of the use of cetuximab in refractory
metastatic colorectal cancer by the European Medicines Agency
(EMEA) in June 2004. Studies have subsequently concentrated on
the use of cetuximab as a first-line treatment combined with
chemotherapy.
At present, there is a wide variation of practice with regard to
colorectal liver metastases. This extended literature review, there-
fore, aimed to evaluate the clinical role of cetuximab when used as
the first-line treatment of colorectal liver metastases and to deter-
mine its role in clinical practice within the setting of colorectal
liver metastases.
Methods
An up-to-date computer-aided literature search was performed
using the following databases:
1 PubMed/MEDLINE (1966 to date; National Library of Medi-
cine, Bethesda, MD, USA);
2 Athens;
3 Embase (1980 to date; Elsevier Science, New York, NY, USA);
4 The Cochrane Central Register of Controlled Trials (Central);
5 Ovid.
The following key words were used: KRAS, cetuximab, erbitux,
metastatic colorectal cancer, colorectal liver metastases, singly or
in combination. To ensure an up-to-date literature search, the
search was initially restricted to the last 6 years (2006–2011). To
maximize this search, backward chaining of reference lists from
retrieved papers was also undertaken. To ensure all possible litera-
ture was included, both published and unpublished, contact was
made with the manufacturers of cetuximab, Merck Serono.
However, in spite of their reply no further data were added to this
review, and they had no input into the literature review.
All randomized controlled trials and cohort studies over the
defined time period were included. It was limited to papers only
published in the English language, involving human participants
and studies that used cetuximab as a first-line treatment for color-
ectal liver metastases. A total of 15 studies relating to the clinical
application of cetuximab as a first-line treatment of colorectal liver
metastases were included. (Fig. 1: QUORUM flowchart)
Literature review
Cetuximab as a first-line treatment for colorectal
liver metastases
Many studies have assessed the role of cetuximab when combined
with various chemotherapy agents. One of the most common
chemotherapy regimens is FOLFOX, a combination of folinic acid
(leucovorin), fluorouracil and oxaliplatin; along with FOLFIRI, a
combination of folinic acid (FA), fluorouracil (5-FU) and irinote-
can. Other described combinations include the use of capecitab-
ine and bevacizumab. This review will assess the role and efficacy
of cetuximab when combined with these various chemotherapy
agents.
Cetuximab in combination with FOLFOX, FOLFIRI or both
When considering any potential new treatment, it is of prime
importance to first establish the safety of such a treatment for
human subjects. Folprecht et al. 20066 aimed to investigate safety
when cetuximab was used in combination with irinotecan, 5-FU
and FA. This was investigated using a prospective phase I/II trial,
with no control group for comparison or power calculations to
validate the findings. Although 27 patients were recruited, only 21
were included. Documented side effects included an acne-like
rash, asthenia, diarrhoea, hypersensitivity, infection, leucopenia,
mucositis, and nausea and vomiting. They found that cetuximab
did not result in any life-threatening complications, and it was the
increasing dose of 5FU that increased the side effect profile rather
than cetuximab.
This small study provides level 2 evidence to suggest cetuxi-
mab does not alter the pharmokinetics of the chemotherapy
agents used, and the increasing side effect profile is potentially as
a result of an increased dose of 5FU rather than the addition of
cetuximab.
QUORUM diagram for cetuximab review
Potentially relevant publications identified and screened for retrieval
n = 97
Papers excluded n = 36
(animal studies, other languages excluded; only last 6 years included)
Papers retrieved from more detailed examination
n = 61
Papers excluded n = 40
(only those were cetuximab was first-line treatment were included)
Papers retrieved from more detailed examination
n = 21
Papers excluded n = 6
(case series excluded)
Papers with usable information, by outcome, n = 15
Figure 1 QUORUM diagram for cetuximab review
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Tabernero et al. 20077 further evaluated the safety and efficacy
of cetuximab with FOLFOX-4 (oxaliplatin, FU, and LV) using a
multicentre, non-controlled, open-label phase II study, with
reproducible methodology. The lack of a control reduces its
rigour. An adequately powered sample size of 62 patients
enhanced the validity of the findings. An overall response of 72%
was described, with a median progression-free survival of 12.3
months, and an overall survival of 30 months. Adverse events
included diarrhoea, neutropenia and paraesthesia.
Overall, this study provides level 2 evidence to suggest the
cetuximab is safe in clinical practice. However, in isolation and
without comparison it cannot provide adequate evidence to
support the addition of cetuximab in clinical practice.
Several large studies have been published in recent years to
assess the role of cetuximab in the first-line management of meta-
static colorectal cancer.
The OPUS study by Bokemeyer et al. in 20098 aimed to assess
the best overall response of cetuximab combined with oxalipla-
tin, leucovorin and fluorouracil (FOLFOX-4) and compare with
FOLFOX-4 alone as the first-line treatment of colorectal liver
metastases. The strengths of this open-label, randomized multi-
centre phase II study include the large adequately powered
sample size, true randomization and the subsequent updated
publication in 2011, all increasing the rigour of the study and its
subsequent validity.9
Overall, the addition of cetuximab improved the overall
response from 36% to 46%; however, this was not statistically
significant. In the KRAS subgroup, in KRAS wild-type patients the
overall response increased from 37% to 61% (P = 0.011) by adding
cetuximab. In the updated analysis published in 2011, the overall
response increased from 34% to 57% (P = 0.0027). In the entire
study cohort, the progression-free survival was the same in both
groups, whereas in the KRAS wild-type group, it was higher in
those who received cetuximab (P = 0.0163). In the updated analy-
sis, in the cetuximab group, survival was significantly better in
those patients who were KRAS wild type (22.8 versus 13.4
months), and in all KRAS wild-type patients, those who received
cetuximab had a higher chance of surgical intervention (12%
versus 3%, P = 0.02).
In summary, the OPUS study provides level 1 evidence to dem-
onstrate an increased response to treatment when cetuximab was
added to the standard chemotherapy regimen, especially in those
patients who were found to be KRAS wild type. The more recent
2011 publication enhances the validity of the OPUS study find-
ings, adding strength to the theory that KRAS wild-type tumours
have a better response to cetuximab. This, therefore, provides
evidence that in clinical practice cetuximab may not be the most
appropriate to all patients, but only those who are KRAS wild type
further highlighting the need for an individual approach to cancer
treatment to optimize the response.
When considering treatment, the overall aim in colorectal liver
metastases is to first make unresectable disease resectable. The
CELIM study aimed to assess the effectiveness of cetuximab in
combination with chemotherapy for unresectable CRLM to
downsize tumours for curative resection in the form of a prospec-
tive randomized trial.10 However, the methodology had several
inherent weaknesses: 17 centres recruited participants introduc-
ing undeclared selection bias, the groups were not truly rand-
omized and funding was provided by the drug company reducing
the overall rigour of the methodology. The lack of a control group
makes it difficult to draw any meaningful, valid conclusions
regarding cetuximab.
Comparing cetuximab plus FOLFIRI with cetuximab plus
FOLFOX-6, overall response rates were 68% compared with 59%
and not statistically significant. The tumour response was higher
in the KRAS wild-type group (70%) compared with the mutant
group (41%; P = 0.008). The R0 resection rate was 38% in group
A and 30% in group B. In those patients who did have a resec-
tion, the median time to intervention was noted to be 5.1
months. At the time of publication, disease-free and overall sur-
vival data are not yet matured; these are important parameters,
which would further enhance the findings of this study and have
important implications regarding whether cetuximab should be
introduced into clinical practice. The adverse effects associated
with these treatment options include 34% skin reactions and
23% neutropenia.
This study provided level 1 evidence that compared with his-
torical controls, chemotherapy with cetuximab yielded a higher
response rate and therefore increased resectability. On the basis of
this study alone, as a result of the highly selective group with no
control group or long-term outcome data, no conclusion can be
drawn regarding the role of cetuximab in clinical practice. The
variation in outcome depending on KRAS status does, however,
further strengthen the argument for the introduction of KRAS
testing routinely in metastatic colorectal cancer.
The CRYSTAL study, reported by Van Cutsem et al. in 2009,11
aimed to investigate the efficacy of cetuximab plus irinotecan,
fluorouracil and leucovonin (FOLFIRI) as the first-line treat-
ment for metastatic colorectal cancer, and sought to find an
association between the mutation status of KRAS and clinical
response to cetuximab It prospectively compared FOLFIRI with
cetuximab and FOLFIRI in which both groups were truly
randomized. This was an adequately powered study in which,
2020 patients were screened, of which 1217 patients underwent
randomization, with 1198 subsequently treated (599 in each
group).
It found cetuximab plus FOLFIRI reduced the risk of disease
progression by 15% compared with FOLFIRI alone (P = 0.048).
The response was higher in the cetuximab group (46.9% versus
38.7%), as was the rate of surgical resection (7% versus 3.7%).
KRAS wild-type patients had a higher median survival and a
higher response rate to cetuximab at 59.3%. This study should be
interpreted with caution as two-thirds of patients had further
chemotherapy regimens introducing a confounding variable.
The CRYSTAL study provided level 1 evidence demonstrating
that cetuximab reduces the risk of progression in metastatic
HPB 13
HPB 2013, 15, 11–17 © 2012 International Hepato-Pancreato-Biliary Association
colorectal cancer when used in combination with FOLFIRI as
first-line treatment, and is of particular benefit in patients with
KRAS wild-type tumours.
The validity of these results is further strengthened by a more
recent publication of follow-up data by Van Cutsem et al. 2011,12
which described a definite survival benefit from adding cetuxi-
mab. In KRAS wild-type patients, those who received cetuximab
had a reduction in disease progression. To date, cetuximab con-
sistently has demonstrated an increased response rate and better
overall survival especially in those patients who are KRAS wild
type; however, it still remains that these findings are in a highly
selective sub group of patients which may not be representative of
routine practice.
The CECOG trial is a prospective study of cetuximab and
FOLFOX-6 or FOLFIRI by Ocvirk et al. 2010,13 aimed to assess the
efficacy and safety of cetuximab combined with two chemo-
therapy regimens in patients with unresectable metastatic color-
ectal cancer, with robust methodology and an adequately powered
sample size, which found no statistical difference in the outcome
of both groups The combination of cetuximab and FOLFOX6 had
a superior outcome in KRAS wild-type patients. KRAS wild type
had a longer median survival of 22.5 months as compared with
15.2 months of the KRAS mutant (P = 0.02). With regard to
survival rates, the KRAS wild-type survival rate at 24 months was
43% compared with 14% in the KRAS mutant group.
Although this is a smaller study when compared with studies
such as the CRYSTAL study, it provides level 1 evidence the
support the use of cetuximab when combined with chemo-
therapy, either FOLFIRI or FOLFOX6, in terms of clinical
outcome especially progression-free survival. No significant dif-
ferences were found for cetuximab with FOLFOX6 or FOLFIRI in
the first-line treatment of metastatic colorectal cancer. In relation
to clinical practice, the validity of these results is significantly
reduced by the absence of a control arm, chemotherapy alone.
When considering the role of KRAS testing, superior outcomes
were only found when cetuximab was combined with FOLFOX6.
This has potential implications to clinical practice, challenging the
previous data to suggest cetuximab improves outcome in KRAS
wild-type tumours, whereas it may also be dependent on what
chemotherapy regimen cetuximab is combined with.
In the POCHER trial, by Garufi et al. 2010,14 the effectiveness of
cetuximab and chronomodulated irinotecan, 5FU, FA and oxali-
platin administered as neoadjuvant chemotherapy to increase the
respectability of colorectal liver metastases was assessed, using a
phase II prospective trial involving 2 centres over a 2-year period.
A partial response was obtained in 34 patients, with an objective
response rate of 79.1%. Twenty-six patients underwent radical
liver surgery with a 60% rate of a R0 resection; 2 had R1 resections
whereas 145 (n = 6) were unresectable at laparoscopy. Overall,
only two had a complete pathological response.
After a median follow-up of 22 months, 16% were alive without
recurrence, 39.5% were alive with recurrence, 2 were lost to
follow-up and 39.5% died as a result of disease progression. Of the
seven without recurrence, five were KRAS wild-type. The overall
progression-free survival was 14 months, 15 months in resectable
patients and 9 months in those with unresectable disease.
This study provides level 2 + evidence regarding the benefit of
surgical resection of colorectal liver metastases in appropriately
selected patients, with a statistically significant improvement in
overall survival in those patients who were deemed resectable after
resection. Weaknesses include a lack of a control group and a small
sample; however, it is not highly selective. As only two patients had
a complete pathological response, this study may suggest that the
use of chemotherapy in addition to cetuximab is not in isolation
but used as a method of down staging the disease. Further rand-
omized controlled studies are required to validate this further.
The MRC COIN trial is the largest prospective randomized
phase 3 trial of cetuximab combined with chemotherapy, with the
population representative of clinical practice within the UK along
with the added advantage of prospective KRAS testing.15 Maughan
et al. aimed to assess the effect on overall survival of adding
cetuximab to standard chemotherapy in the first-line treatment of
advanced colorectal cancer, with robust methodology in which
there was reduced selection bias. It involved three arms: arm A
consisted of oxaliplatin plus fluoropyrimidine chemotherapy;
arm B consisted of arm A plus cetuximab; and arm C was inter-
mittent chemotherapy alone. This study solely compared arm A
with B, in which the primary outcome is overall survival in
patients with KRAS wild-type tumours. Progression-free survival,
response and toxic effects were all evaluated.
In KRAS wild-type patients, the median survival in both groups
was similar; however, there was a higher response in the cetuximab
group in spite of no increase in curative resection. Irrespective of
the treatment undertaken, the median overall survival was shorter
in patients with mutations of any three of the KRAS oncogenes
studied (n = 706, 13.6 months) compared with wild-type tumours
[n = 581; 20.1 months (P < 0.0001)]. Fifty-seven per cent (n = 209)
of patients with KRAS wild-type lesions in the control group had
a partial or complete response versus 64% (n = 232) in the cetuxi-
mab group (P = 0.049). No increase in potential curative liver
resection was noted; 13% in the KRAS wild-type control group
compared with 15% in the cetuximab group (P = 0.74). Cetuxi-
mab was also noted to have a higher incidence of skin, gastroin-
testinal and other toxic effects.
This large robust study, in contradiction with previously pub-
lished studies, provides level 1 evidence suggesting there may not
be any overall benefit from cetuximab in a population representa-
tive of UK clinical practice.
Using the same data set, Adams et al.,16 aimed to compare
intermittent versus continuous combination chemotherapy in
advanced colorectal cancer, along with the assessment of the
effect of the addition of cetuximab to continuous oxaliplatin
and fluoropyrimidine combination chemotherapy, which were
described previously.
This study, provides level 1 evidence to demonstrate that
intermittent chemotherapy when combined with cetuximab is
14 HPB
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associated with an improved quality of life, shortened time on
chemotherapy, a reduction in the number of hospital visits
required and a minimal difference in overall survival. Interest-
ingly, this study reported a shorter survival than other reported
trials, which may be as a result of more advanced disease at the
time of presentation along with the inclusion of a larger number
of centres with different confounding approaches to management.
Overall, the COIN trial questions the efficacy of cetuximab in a
validated study with a clinically relevant cohort of patients.
Cetuximab in combination with oxaliplatin and
capecitabine (XELOX)
Borner et al.17 aimed to determine the activity and tolerability of
adding cetuximab to oxaliplatin and capecitabine (XELOX) in the
first-line treatment of metastatic colorectal cancer. Using robust
methodology it concluded this combination improves overall
outcome.
Partial response rates were higher with cetuximab (arm B) (arm
B 41% versus arm A 14%). The reviewed partial response rates,
which were determined independently, were 21.6% in arm A com-
pared with 43.2% in arm B, whereas retrospective overall response
rates were 35.1% versus 54%. The median time to treatment
failure was 5.7 months in arm A compared with 7.2 months in
arm B. The median survival was 16.5 months in arm A and 20.5
months in arm B.
This study, however, provided level 1 evidence to suggest that by
combining cetuximab with oxaliplatin and capecitabine (XELOX)
improves the overall outcome. As a result of patient drop out, the
sample size did not reach an adequate size to power the study
significantly, and therefore any findings should be interpreted
with caution. In isolation, the findings of the study would not be
sufficient to change clinical practice; however, it would suggest the
need for further randomized phase III trials to validate these
findings.
Cetuximab in combination with capecitabine, oxaliplatin
and bevacizumab
The CARIO2 trial assessed cetuximab in combination with
capecitabine, oxaliplatin and bevacizumab.18 Although the meth-
odology was not entirely robust, as a result of the entire sample
not being included; this publication provides level 2 evidence that
this is a safe drug, which can be given to patients without a major
risk of severe side effects.
A more recent publication by Tol et al.19 aimed to assess the
effect of adding the anti-epidermal growth factor receptor
(EGFR) antibody cetuximab to a combination of capecitabine,
oxaliplatin and bevacizumab for the first-line treatment of
metastatic colorectal cancer.
This study provides level 1 evidence to contradict many previ-
ous studies, in which it demonstrated with statistically signifi-
cance that cetuximab when combined with capecitabine,
oxaliplatin and bevacizumab did not improve progression-free
survival. In fact it actually decreased progression-free survival and
resulted in a poorer quality of life. This was a large study with
rigorous, robust methodology. Unlike other studies, it does dem-
onstrate that KRAS wild-type tumours respond more favourably
than KRAS mutant tumours when cetuximab was used. However,
neither group given cetuximab had a better outcome than those
just received capecitabine, oxaliplatin and bevacizumab alone.
This however may not be relevant to clinical practice owing to the
multi-centred nature of this study in which practice may not be
representative of UK clinical practice.
Survival
Finally a large observational study from two eminent academic
centres in United States performed from 1996 to 2006 found
significant improvement in the survival of patients in colorectal
liver metastases in recent years.20 Kopetz et al. aimed to evaluate
the changes in survival of patients with metastatic colorectal
cancer using both multi-institutional and population-based data-
bases and to associate these changes to hepatic resection utiliza-
tion and temporal trends in improvements in chemotherapy.
No significant difference in median survival was noted from
1990 to 1997 with a median survival of 14.2 months; however, a
significant improvement was seen over later years to a maximum
of 29.2 months by 2004 to 2006 (P < 0.05). Five-year survival
increased from 9.1% in 1990–1997, to 19.2% in 2001–2003, with
proportional hazard modelling of survival predicting a 5-year
survival of 32% from 2004–2006.
To establish the impact of chemotherapy and to exclude the
influence of hepatic resections, overall survival was repeated after
censoring patients with hepatic resections at the time of surgery.
When reviewing chemotherapy agents in isolation, patients diag-
nosed in 2004–2006 had a significant improvement in their overall
survival, with a hazard ratio of 0.53 (95% CI, 0.45 to 0.62; P <
0.001). The one noticeable difference during this time period was
the introduction of cetuximab and becavizumab.
Advances in chemotherapy along with the introduction of
cetuximab and bevacizumab have been attributed to this signifi-
cant overall improvement. Although it may not be possible to
isolate cetuximab, it does provide evidence that changes in clinical
practice have substantially improved outcome. In reference to
current clinical practice, it would suggest that optimization of
current chemotherapy agents and the development of novel
agents has improved survival overall; however, by excluding those
patients with poor performance status this may in fact be an
overestimation of survival.
Discussion
In summary, the management of colorectal liver metastases has
significantly advanced within the last decade. Many changes are
now established routine practice including the role of PET-CT
scanning in pre-operative scanning, laparoscopic surgical resec-
tion and more aggressive resection with the definition of resect-
able disease being redefined.
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Fifteen studies reviewed the clinical application of cetuximab in
the first-line treatment of unresectable colorectal liver metastases,
all of which were prospective. The main findings are summarised
in Table 1. Seven studies also included sub-group analysis depend-
ing on KRAS mutational status, with only one study performing
KRAS mutational status prospectively.
Studies such as OPUS and CRYSTAL have consistently demon-
strated that the addition of cetuximab to standard first-line
chemotherapy agents (FOLFOX and FOLFIRI) significantly
improved progression-free survival, overall survival and surgical
resection rates (grade B evidence), especially in the setting of
KRAS wild-type tumours. Tumour response rates have been
shown to be directly related to increased surgical resection rates.
Although the absolute numbers of tumours that convert from
unresectable to resectable remain low, there is a statistically sig-
nificant increase, resulting in an increasing role for liver surgeons
in the management of these patients.
However, the MRC COIN trial, the largest prospective trial
performed in the UK, has cast doubt on the conclusions drawn
from the previous evidence. With its robust methodology it found
cetuximab did not have any additional benefit when combined
with standard chemotherapy regimens (grade B evidence). The
chemotherapy regimen used however largely differs to previously
published studies, with XELOX being most commonly used; and
this may in part explain the difference to previously published
data. In addition to this, the study participants were largely pal-
liative care patients with multiple sites of metastatic disease. The
findings are therefore not representative of patients with liver only
disease and cannot be directly applied to this subgroup. On
further sub-analysis, it did however report that progression-free
survival was more likely to be superior in patients with one site of
metastatic spread only.
The majority of evidence suggested an overall benefit in adding
cetuximab to standard chemotherapy treatment. This has usually
been performed in a highly selected group of patients, especially
those with one metastatic site, with the potential of making pre-
viously unresectable disease resectable.
To date, the clinical benefit of cetuximab has been studied
extensively; however, in this modern era of economic decline it is
also imperative to consider the cost effectiveness of such treat-
ment in the NHS. The evidence reinforces the importance of
optimizing treatment on an individual basis, especially depending
on their tumour biology.
In conclusion, therefore, in the era of evidence-based medicine
the literature does not support the routine use of cetuximab in the
treatment of colorectal liver metastases. It does however highlight
the need for the optimization of treatment on an individual basis,
especially the use of cetuximab in KRAS wild-type tumours only.
Table 1 Summary of clinical findings of referenced papers
Study Description Overall response R0 resection PFS (months) OS (months)
OPUS (n = 337) Bokemeyer 2009 Cetuximab 46% Not available 7.2 Not available
Without cetuximab 36% 7.2
OPUS 2011 Cetuximab 46% Not available 7.2 18.3
Without cetuximab 36% 7.2 18.0
CELIM (n = 114) Folprecht 2010 FOLFOX6 + Cetuximab 68% 38% Not available Not available
FOLFIRI + cetuximab 59% 30%
CRYSTAL (n = 1198) Van Cutsem 2009 Cetuximab 46.9% 4.8% 8.9 19.9
Without cetuximab 38.7% 1.7% 8.0 18.6
CRYSTAL Van Cutsem 2011 Cetuximab 57.3% Not available 9.9 23.5
Without cetuximab 39.7% 8.4 20.0
CECOG (n = 115) Ocvirk 2010 Cetuximab 40% Not available 8.6 17.4
Without cetuximab 36% 8.3 18.9
POCHER (n = 43) Garufi 2010 Cetuximab 79.1% 60% 14 37
Without cetuximab
MRC COIN (n = 1630) Maughan 2011 Cetuximab 64% 15% 8.6 17.9
Without cetuximab 57% 13% 8.6 17
MRC COIN (n = 1630) Adams 2011 Cetuximab Not available Not available 7.4 14.4
Without cetuximab 8.4 15.8
Borner 2008 (n = 64) Cetuximab 54% Not available Not available 20.5
Without cetuximab 35.1% 16.5
Tol 2009 (n = 755) Cetuximab 52.7% Not available 9.4 19.4
Without cetuximab 50% 10.7 20.3
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With the increasing response rates associated with cetuximab and
the subsequent opportunity to make unresectable liver metastases
resectable, this will potentially increase the role of liver surgeons in
the management of these previously unresectable patients. Prior
to a change in clinical practice, the cost-effectiveness of this treat-
ment needs to be considered in more detail. At present the evi-
dence is not robust enough to change routine clinical practice, and
establish guidelines to include the use of cetuximab.
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